T-Cure

T-Cure, founded by early pioneers in T-cell receptor (TCR) therapy, is committed to finding treatments for human cancer through its advanced TCR-T technology. With its proprietary iSORT TCR discovery platform, T-Cure is poised to rapidly advance its therapeutic candidate pipeline. The company believes its TCRs hold great promise in treating patients whose conditions cannot be addressed by current methods.